FAST III is a randomized controlled, open-label, multicenter, international, non-inferiority, strategy trial aiming to enroll a total of 2228 patients, in 7 European countries and approximately 35 hospitals. The FAST III trial is performed in accordance with the Declaration of Helsinki, Good Clinical Practice (GCP), ISO 14155:2020, EC requirements and country specific regulations.